Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK2269 Monotherapy and Combination With Docetaxel in Solid Tumors
NCT06266299Phase 1Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Jan 2024
- Primary completion
- Mar 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of KK2269 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting Toxicity at 21 days and Adverse Events at 1 year. Started Jan 2024; status: active, not recruiting.
02
Drugs
KK2269
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06266299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266299.